Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
IMV IMV		$0.66	$0.48 ▼ $12.70	$9.63M	0.95	233,607 shs	44,800 shs
RVX Resverlogix	C$0.06	C$0.06	C$0.05 ▼ C$0.16	C$16.33M	0.78	37,265 shs	36,650 shs
VINC Vincerx Pharma	$0.95 +9.2%	$4.13	$0.61 ▼ $9.37	$20.34M	1.09	1.27 million shs	420,238 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
IMV IMV	0.00%	0.00%	0.00%	0.00%	+8.22%
RVX Resverlogix	0.00%	-8.33%	-8.33%	-15.38%	-66.67%
VINC Vincerx Pharma	+2.24%	-0.11%	-82.69%	-24.43%	-8.55%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	2.2892 of 5 stars	3.5	4.0	0.0	0.0	1.7	2.5	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A
IMV IMV	2.00	Hold	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	3.00	Buy	$5.00	426.32% Upside

Current Analyst Ratings

Latest FRX, VINC, RVX, IMV, and BVXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/9/2024	VINC Vincerx Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/1/2024	VINC Vincerx Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
IMV IMV	$330K	0.00	N/A	N/A	($0.69) per share	0.00
RVX Resverlogix	N/A	N/A	C$0.00 per share	132.50	C($0.26) per share	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IMV IMV	-$37.99M	-$4.59	N/A	N/A	N/A	-11,547.42%	-12,695.41%	-104.84%	N/A
RVX Resverlogix	-C$12.82M	-C$0.05	N/A	∞	N/A	N/A	N/A	-37.10%	5/9/2024 (Estimated)
VINC Vincerx Pharma	-$40.16M	-$1.89	N/A	N/A	N/A	N/A	-187.73%	-126.26%	5/9/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRX Forest Road Acquisition	N/A	0.37	0.37
IMV IMV	N/A	2.93	2.93
RVX Resverlogix	N/A	0.11	0.04
VINC Vincerx Pharma	N/A	2.63	2.63

Ownership

Institutional Ownership

Company	Institutional Ownership
FRX Forest Road Acquisition	N/A
IMV IMV	15.37%
RVX Resverlogix	N/A
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
FRX Forest Road Acquisition	N/A
IMV IMV	0.33%
RVX Resverlogix	43.19%
VINC Vincerx Pharma	20.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
IMV IMV	97	11.71 million	11.67 million	Optionable
RVX Resverlogix	19	272.17 million	N/A	Not Optionable
VINC Vincerx Pharma	41	21.41 million	17.00 million	Not Optionable

FRX, VINC, RVX, IMV, and BVXP Headlines

Source	Headline
	Vincerx Pharma, Inc. Common Stock (VINC) nasdaq.com - April 23 at 2:06 AM
	AACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survival fiercebiotech.com - April 18 at 12:36 PM
	Analyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC) americanbankingnews.com - April 16 at 2:40 AM
	Agendia’s BluePrint Included in German Oncology Group Guidelines finance.yahoo.com - April 12 at 9:45 AM
	Vaccines, Next-Gen Approaches Target the Toughest Cancers: AACR biospace.com - April 12 at 9:45 AM
	The Rise of Zyn: The Oral Nicotine Product Going Viral finance.yahoo.com - April 10 at 4:08 PM
	Vincerx Pharma Inc (VINC) Gets a Buy from Leerink Partners markets.businessinsider.com - April 10 at 9:44 AM
	Vincerx (VINC) Tumbles on Results From Cancer Therapy Study zacks.com - April 9 at 2:36 PM
	ACOR, HUBC and DATS among pre-market losers msn.com - April 9 at 9:19 AM
	Vincerx in selloff after early-stage data for cancer therapy msn.com - April 9 at 9:19 AM
	Cantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC) marketbeat.com - April 9 at 8:49 AM
	Why Is Vincerx Pharma (VINC) Stock Down 64% Today? investorplace.com - April 9 at 8:40 AM
	Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 globenewswire.com - April 8 at 4:30 PM
	FY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC) marketbeat.com - April 4 at 9:13 AM
	Q1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrs marketbeat.com - April 3 at 6:00 AM
	VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023 investorplace.com - April 2 at 8:06 AM
	Vincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update finanznachrichten.de - April 1 at 4:30 PM
	Vincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgerald marketbeat.com - April 1 at 12:23 PM
	Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 finance.yahoo.com - April 1 at 10:47 AM
	Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look finance.yahoo.com - March 29 at 8:49 PM
	Vincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024 marketwatch.com - March 29 at 3:48 PM
	Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update globenewswire.com - March 29 at 3:20 PM
	Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2% marketbeat.com - March 28 at 8:34 AM
	Vincerx Pharma (VINC) Set to Announce Earnings on Tuesday marketbeat.com - March 25 at 7:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Intuitive Surgical Leads the Robotic Surgery Movement
April 22, 2024 6:10 AM
View Intuitive Surgical Leads the Robotic Surgery Movement

All Headlines

Company Descriptions

Forest Road Acquisition

NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

IMV

NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Resverlogix

TSE:RVX

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Vincerx Pharma

NASDAQ:VINC

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial